Adverse Reactions/Side Effects Adverse events that are clearly related to sotalol (AF) are those which are typical of its Class II (beta-blocking) and Class III (cardiac action potential duration prolongation) effects. The common documented beta-blocking adverse events (bradycardia, dyspnea, and fa...
It has both beta-adrenoreceptor blocking (Vaughan Williams Class II) and ardiac action potential duration prolongation (Vaughan Williams Class III) antiarrhythmic properties. It is used (usually as the hydrochloride salt) for the management of ventricular and supraventricular arrhythmias. View all 3.2...
hERG potassium channel blocking lengthens the time until repolarization, as seen in the action potential (top) and ECG (bottom), resulting in LQT. Sign in to download full-size image Figure 16.4. ECG showing torsades de pointe (TdP) arrhythmia. The number of drugs that induce TdP is ...
Class III drugs prolong the action potential duration of myocardial cells, resulting in a lengthening of the effective refractory period. This pharmacologic activity has antiarrhythmic properties, but it may induce a distinctive form of proarrhythmia known as torsades de pointes. Amiodarone and d,l-...
Your doctor may already be aware of the risks, but has determined that this is the best course of treatment for you and has taken appropriate precautions and is monitoring you closely for any potential complications. You should seek immediate medical attention if you develop sudden dizziness, ...
Pharmacodynamic Properties In both animals and man, the pharmacodynamic properties of sotalol are dominated by a composite effect of β-blockade and the propensity to prolong the cardiac action potential duration. Sotalol has one-third the β-blocking potency of propranolol; it is devoid of intrinsic...
In both animals and man, the pharmacodynamic properties of sotalol are dominated by a composite effect of β-blockade and the propensity to prolong the cardiac action potential duration. Sotalol has one-third the β-blocking potency of propranolol; it is devoid of intrinsic sympathomimetic actions ...
we do not expect any potential bias in our analysis due to the choice of the QT correction formula. However, we acknowledge that this is a limitation of our study, and future studies must include a thorough evaluation of the QT-RR relationship after sotalol administration. If bias due to th...
It has both beta-adrenoreceptor blocking (Vaughan Williams Class II) and ardiac action potential duration prolongation (Vaughan Williams Class III) antiarrhythmic properties. It is used (usually as the hydrochloride salt) for the management of ventricular and supraventricular arrhythmias....
ObjectivesTo determine the pharmacokinetics of sotalol at multiple oral dosages in unfasted horses, as well as the effects on electro- and echocardiographic measurements, right atrial and ventricular monophasic action potential (MAP) and effective refractory period (ERP). Study designPlacebo controlled,...